Latest California Healthline Stories
Prestigiosos hospitales se lanzan al negocio de terapias con células madre no aprobadas
Los tratamientos típicos consisten en inyectar las articulaciones de los pacientes con sus propias células grasas o de médula ósea, o con extractos de plaquetas. No está comprobado científicamente que funcionen.
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Pacientes experimentan con drogas recetadas para luchar contra la vejez
Aún no se han realizado ensayos clínicos rigurosos a gran escala para estudiar el proceso de envejecimiento. Así y todo, pacientes experimentan con drogas para detener el paso del tiempo.
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
Americans Cross Border Into Mexico To Buy Insulin At A Fraction Of U.S. Cost
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Listening To Older Patients Who Want To Stop Dialysis
Older adults with advanced kidney disease sometimes want to stop dialysis but often meet resistance from doctors, new research shows. We explore options available to these patients, including conservative care.
Adultos mayores vulnerables logran volver a ser independientes
El programa para personas mayores vulnerables de bajos ingresos Community Aging in Place — Advancing Better Living for Elders (CAPABLE) ayuda a los abuelos a vivir independientemente.
Frail Seniors Find Ways To Live Independently
A pilot program for frail low-income seniors provides much-needed help in dealing with “daily activities” and offers practical solutions.
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.